Aspergillosis Market Overview Report 2026: Pipeline Holds 37 Molecules, With No Assets In The Pre-Registration Stage, Four Assets In Phase III Development, And Another Four In Phase II

(MENAFN- GlobeNewsWire - Nasdaq) India is poised for significant market opportunities in aspergillosis therapeutics due to rising incident cases. Although the market is currently saturated with generics, there is potential in advancing pipeline assets in Phase II and III, amid active mergers and strategic alliances, to drive future market growth.

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Aspergillosis: Market View" report has been added to ResearchAndMarkets's offering.

This reports provides a data-driven overview of the current and future competitive landscape in Aspergillosis Therapeutics. The report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Report Scope

• In 2024 and 2029, India is anticipated to have the highest number of diagnosed incident cases of aspergillosis, representing a large portion of global cases.
• Currently, the aspergillosis market is saturated with generic drugs. Triazoles, polyenes, and echinocandins are primarily used to manage aspergillosis.
• The aspergillosis pipeline holds 37 molecules, with no assets in the pre-registration stage, four assets in Phase III development, and another four in Phase II.
• Over the past decade, 226 clinical trials have been conducted in aspergillosis. The year with the most studies initiated was 2021, with 38 trials, followed by 2023 with 32 trials.
• During the past 28 months, 16 mergers and acquisitions and three strategic alliances involving companies developing aspergillosis assets were completed globally.
• The aspergillosis market is unlikely to see an influx of drugs in the near term, with no products in pre-registration and only four products in Phase III development.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Aspergillosis Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Aspergillosis Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN09042026004107003653ID1110963025